Genentech公司的抗癌新药Bevacizumab(rhu鄄MAb鄄VEGF,商品名:Avastin)于2004年2月26日获得美国食品和药物管理局(FDA)的批准上市用于一线治疗晚期结直肠癌,这是世界上首个批准上市的血管内皮生长因子(VEGF)抑制剂。对900多名已转移的结肠直肠癌患者进行的临床试验发现,同时接 Genentech’s anti-cancer drug Bevacizumab (rhu-MAb-VEGF, trade name: Avastin) was approved by the U.S. Food and Drug Administration (FDA) on February 26, 2004 for first-line treatment of advanced colorectal cancer, which is The world’s first approved vascular endothelial growth factor (VEGF) inhibitor. Clinical trials of more than 900 patients with metastatic colorectal cancer have found that simultaneous access